Recent News
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the…
Improving Mesothelioma Diagnosis
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos exposure, mostly affects the pleura. The pleura is the membrane that surrounds the lungs. It can also harm tissues like the…
Changing Gut Bacteria Could Improve Effectiveness of Certain Treatments for Mesothelioma
A new cancer study has found that certain gut bacteria could influence a person’s immune system when fighting mesothelioma, an aggressive cancer of the linings of certain areas of the…
New Testing for Asbestos in Talc Based Products
In 2023, Congress passed a new law requiring that the U.S. Food and Drug Administration release new industry standards for asbestos testing in products. The agency will require all talc-containing…
New Blood Test for Mesothelioma
Mayo Clinic researchers have created a new blood test that is better able to detect mesothelioma. The result could be earlier diagnoses. It could also lead to new options for…
Keytruda and Chemotherapy Approved for the Treatment of Mesothelioma
A new first line treatment was approved by the U.S. Food and Drug Administration for the treatment of pleural mesothelioma that cannot be removed by surgery. The approval is specifically…
Immune Checkpoint Inhibitors for the Treatment of Mesothelioma
Mesothelioma is a rare, aggressive cancer mainly caused by asbestos exposure. One treatment that is giving hope to patients and caregivers is the use of immune checkpoint inhibitors. A new…
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Ipilimumab and Nivolumab for the Treatment of Mesothelioma
Mesothelioma is a difficult diagnosis to receive. With this diagnosis comes treatment regimens and their effects on the body. The United Kingdom has a new set of standard treatments for…
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare, yet aggressive cancer mainly caused by asbestos exposure. There are very limited options for treatment. This is especially true for elderly patients. Conventional therapies might not…
